The dual SYK/JAK inhibitor, Cerdulatinib, demonstrated good clinical response in relapsed/refractory PTCL patients in a phase 2 clinical trial [59]. This evidence concerns the gene SYK and mature T-cell and NK-cell non-Hodgkin lymphoma.